Nancy Lin, MD
Dana-Farber Cancer Institute
Topic Presenter
Financial Disclosure
Consulting Honoraria: Seattle Genetics, Daichii-Sankyo, AstraZeneca, Olema Pharmaceuticals, Janssen, Blueprint Medicines, Stemline/Menarini, Artera Inc., Eisai, Shorla Oncology
Consultant
Institutional Research Support: Genentech, Pfizer, Merck, Seattle Genetics, Zion Pharmaceuticals, Olema Pharmaceuticals, AstraZeneca
Contractor
Grant Or Contract
Royalties – Up to date (book)
Royalties
Travel: Olema, AstraZeneca, Daichii Sankyo
Other